Skip to content

Rebecca Harding

9 papers in the library · 189 citations · publishing 2023-2025

Papers

Sort Most recent Most cited

Understanding Neuroplasticity Induced by Tryptamines (UNITy): Understanding Neuroplasticity Induced by Tryptamines: Rewiring Maladaptive Memories in Hazardous Drinking with Memory Reactivation and Dimethyltryptamine (DMT)

Open Science Framework October 20, 2025 Natalia Fernandez‐Vinson, Roger Atkins, Marcus J. Glennon et al.

This study examines the existence and mechanistic underpinnings of lasting neural, cognitive, and behavioural plasticity in response to N-N-dimethyltryptamine (DMT) in a hazardous drinking population. It combines behavioural, neuroimaging, ecological momentary and qualitative data to gain a holistic understanding of potential mechanisms of therapeutic change following DMT. Primarily, we test...

Correction: Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.

Mol Psychiatry July 1, 2025 Rebecca Harding, Neomi Singer, Matthew B. Wall et al. correction

The following part of the abstract had a minor error: ‘Following PT, there was greater activation in the ventromedial prefrontal cortex and sensory regions, and reduced activation in the angular gyrus.’ This is now corrected to ‘Following PT, there was decreased activation in the ventromedial prefrontal cortex and angular gyrus, and greater activation in sensory regions.’ The original article...

The landscape of ketamine use disorder: Patient experiences and perspectives on current treatment options.

Addiction (Abingdon, England) April 28, 2025 Rebecca Harding, Tamsin Barton, Maeve Niepceron et al. 14 citations

To report the symptoms and aetiology of ketamine use disorder (KUD), gauge the effectiveness of current treatment services and identify strategies to enhance patient access and outcomes. Mixed-methods, cross-sectional questionnaire. Electronic survey from November 2023 to April 2024. Participants were recruited through snowball sampling, social media and referrals from UK addiction treatment...

Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises

Molecular Psychiatry April 26, 2025 Rebecca Harding, Neomi Singer, Talma Hendler et al. 4 citations

Abstract Psilocybin therapy (PT) is emerging as an effective intervention for Major Depressive Disorder (MDD), offering comparable efficacy to conventional treatments like selective serotonin reuptake inhibitors (SSRIs). Music, an emotionally evocative stimulus, provides a valuable tool to explore changes in hedonic and predictive processing mechanisms via expectancy violations, or ‘surprises’....

ASSOCIATIONS BETWEEN ESCITALOPRAM AND PSILOCYBIN THERAPY AND BRAIN RESTING-STATE FUNCTIONAL CONNECTIVITY IN MAJOR DEPRESSIVE DISORDER

The International Journal of Neuropsychopharmacology February 1, 2025 Rebecca Harding, Natalie Ertl, Rayyan Zafar

Abstract Major Depressive Disorder (MDD) is a highly prevalent mental health condition characterized by symptoms including anhedonia, which is defined as diminished pleasure, and impulsivity, which has been linked to increased substance abuse, self-harm and suicidal tendencies. Both anhedonia and impulsivity have been contributed to alterations in reward system function, with the striatum being...

Neuroimaging and the Investigation of Drug-Drug Interactions Involving Psychedelics.

Neurosci Insights October 8, 2024 Matthew B. Wall, Rebecca Harding, Natalie Ertl et al. 3 citations

Psychedelic therapies are an emerging class of treatments in psychiatry with great potential, however relatively little is known about their interactions with other commonly used psychiatric medications. As psychedelic therapies become more widespread and move closer to the clinic, they likely will need to be integrated into existing treatment models which may include one or more traditional...

Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model.

Psychological Medicine December 1, 2023 Paul McCrone, Henry Fisher, Clare Knight et al. 34 citations

There is growing evidence to support the use of the psychedelic drug psilocybin for difficult-to-treat depression. This paper compares the cost-effectiveness of psilocybin-assisted psychotherapy (PAP) with conventional medication, cognitive behavioural therapy (CBT), and the combination of conventional medication and CBT. A decision model simulated patient events (response, remission, and...

Neuroimaging in psychedelic drug development: past, present, and future.

Molecular Psychiatry September 1, 2023 Matthew B. Wall, Rebecca Harding, Rayyan Zafar et al. 39 citations

Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating psychiatric disorders, including depression, addiction, post-traumatic stress disorder, and potentially others. 'Classic' serotonergic psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), which have a key locus of action at the 5-HT2A receptor, form the main focus of this...

Psychedelic therapy in the treatment of addiction: the past, present and future

Frontiers in Psychiatry June 12, 2023 Rayyan Zafar, Maxim Siegel, Rebecca Harding et al. 95 citations

Psychedelic therapy has witnessed a resurgence in interest in the last decade from the scientific and medical communities with evidence now building for its safety and efficacy in treating a range of psychiatric disorders including addiction. In this review we will chart the research investigating the role of these interventions in individuals with addiction beginning with an overview of the...